- Home
- MIRM vs JPC Comparison
MIRM vs JPC Comparison
Compare MIRM & JPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- JPC
- Stock Information
- Founded
- MIRM 2018
- JPC 2003
- Country
- MIRM United States
- JPC United States
- Employees
- MIRM N/A
- JPC N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- JPC Investment Managers
- Sector
- MIRM Health Care
- JPC Finance
- Exchange
- MIRM Nasdaq
- JPC Nasdaq
- Market Cap
- MIRM 2.2B
- JPC 2.5B
- IPO Year
- MIRM 2019
- JPC N/A
- Fundamental
- Price
- MIRM $50.34
- JPC $7.93
- Analyst Decision
- MIRM Strong Buy
- JPC
- Analyst Count
- MIRM 12
- JPC 0
- Target Price
- MIRM $63.17
- JPC N/A
- AVG Volume (30 Days)
- MIRM 397.8K
- JPC 998.5K
- Earning Date
- MIRM 08-06-2025
- JPC 01-01-0001
- Dividend Yield
- MIRM N/A
- JPC 7.57%
- EPS Growth
- MIRM N/A
- JPC N/A
- EPS
- MIRM N/A
- JPC N/A
- Revenue
- MIRM $379,251,000.00
- JPC N/A
- Revenue This Year
- MIRM $35.83
- JPC N/A
- Revenue Next Year
- MIRM $16.83
- JPC N/A
- P/E Ratio
- MIRM N/A
- JPC N/A
- Revenue Growth
- MIRM 69.31
- JPC N/A
- 52 Week Low
- MIRM $28.56
- JPC $5.94
- 52 Week High
- MIRM $54.23
- JPC $7.36
- Technical
- Relative Strength Index (RSI)
- MIRM 69.78
- JPC 56.92
- Support Level
- MIRM $48.78
- JPC $7.88
- Resistance Level
- MIRM $50.05
- JPC $7.98
- Average True Range (ATR)
- MIRM 1.64
- JPC 0.04
- MACD
- MIRM 0.39
- JPC -0.01
- Stochastic Oscillator
- MIRM 87.92
- JPC 50.00
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.